Detection of BRAF Mutations Using a Fully Automated Platform and Comparison with High Resolution Melting, Real-Time Allele Specific Amplification, Immunohistochemistry and Next Generation Sequencing Assays, for Patients with Metastatic Melanoma.
Fiche publication
Date publication
janvier 2016
Journal
PloS one
Auteurs
Membres identifiés du Cancéropôle Est :
Pr HARLE Alexandre, Dr LEROUX Agnès, Pr MERLIN Jean-Louis
Tous les auteurs :
Harlé A, Salleron J, Franczak C, Dubois C, Filhine-Tressarieu P, Leroux A, Merlin JL
Lien Pubmed
Résumé
Metastatic melanoma is a severe disease with one of the highest mortality rate in skin diseases. Overall survival has significantly improved with immunotherapy and targeted therapies. Kinase inhibitors targeting BRAF V600 showed promising results. BRAF genotyping is mandatory for the prescription of anti-BRAF therapies.
Mots clés
Alleles, Automation, High-Throughput Nucleotide Sequencing, Humans, Immunohistochemistry, Melanoma, genetics, Mutation, Neoplasm Metastasis, Proto-Oncogene Proteins B-raf, genetics
Référence
PLoS ONE. 2016 ;11(4):e0153576